
The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Published: August 16th 2024 | Updated: August 19th 2024
Published: March 18th 2024 | Updated: June 3rd 2024
Published: December 7th 2024 | Updated:
Published: December 12th 2022 | Updated:
Published: July 14th 2024 | Updated:
Published: May 18th 2023 | Updated: